Navigation Links
Cancer Screening Costs $88.7B Annually; New Tool Reduces Invasiveness and Price

One thing common to all types of cancer is that it’s a tremendously expensive disease not only to treat, but to test for, as well. The money spent screening for and treating cancer in the United States is estimated to be $88.7 billion every year.(1) Doctors in the U.S. screen patients for cancer more than in any other country that has an advanced healthcare system, sometimes spending as much on screening as is spent on actual treatment.(2) With cancer rates expected to surge 57% worldwide over the next two decades,(3) the economic impact cannot be overlooked.

A substantial portion of rising costs comes from the overuse of imprecise, unnecessary cancer screening tests, particularly for prostate and breast cancer. Paul Crowe, chairman and CEO of NuView Life Sciences, says, “Traditional screening tools can’t get down to a patient-specific level of diagnosis and are often limited in diagnostic ability.” Crowe explains that there has been a huge push to screen people for cancer—regardless of their medical history—but that this may not be the best practice. What’s being seen now is misuse and waste of resources, both of which are driving up healthcare costs for those involved.

By 2017, screening for prostate cancer is expected to cost $17.4 billion annually.(4) However, conventional screening methods, such as prostate-specific antigen (PSA) tests, are often unreliable. False-positive PSA tests lead to expensive, needless biopsies, surgeries and other forms of treatment, all of which can have profoundly negative, lasting impacts on the patient. On the other hand, false-negative tests can lull patients into a false sense of security, putting off treatment until years later, when the disease is far more invasive and expensive to treat, and lessening the patient’s chances of survival.

For prostate cancer, NuView is developing a new precision screening tool based on its NV VPAC1 technology. The cancer-specific urine screening tool can be used to screen for both prostate and bladder cancer by accurately detecting cancer cells in voided urine specimens.(5) This type of screening is more conclusive and less expensive than traditional screening tools like the PSA test, allowing physicians to quickly and correctly diagnose cancer in laboratory-type settings.(5)

NuView is also developing new screening tools for breast cancer, which is notoriously difficult to diagnose at its earliest stages. Mammography is currently the only screening method available, but it cannot reliably detect precancerous lesions.(6) Over 80% of women who receive abnormal mammogram results are subjected to invasive, painful biopsies and other treatments, only to have further tests prove the masses to be benign.(5)

There are 1.6 million breast biopsies performed in the U.S. annually, and approximately 1.3 million of these result in a benign diagnosis.(5) A more highly precise screening tool can drastically reduce the number of unnecessary, invasive breast biopsies performed each year by pinpointing specific breast cancer mutations within a patient. This will also save the country’s healthcare system billions of dollars every year.

Crowe stated, “It’s time to replace current diagnostic tools with precision-based, cancer-specific screening methods. The benefits are two-fold: patients are saved from unnecessary tests and treatment, which increases their quality of life and preserves their health status; and secondly, our healthcare system is saved millions—perhaps billions—of dollars every year that are wasted on pointless tests and therapeutic interventions.”

NVLS is committed to lowering healthcare costs across the board while still providing healthcare providers and patients with a new and more accurate method of obtaining conclusive cancer results.

About NuView Life Sciences:
Founded in 2005, NuView Life Sciences is a biotechnology company located in Park City, Utah, working to reform the way cancer is diagnosed and treated in our modern healthcare system. NuView is focused on creating precision cancer diagnostics and therapeutics to improve patient outcomes while reducing healthcare costs through the development and clinical application of its exclusive peptide analog technology, NV-VPAC1.

Led by a team of industry experts with decades of combined experience in healthcare and medical imaging technologies, NuView is poised to change how we look for and respond to cancer. To learn more about NuView Life Sciences, please visit

1. Economic Impact of Cancer. American Cancer Society.
2. Stop overscreening for cancer. American Enterprise Institute.
3. WHO: Imminent global cancer ‘disaster’ reflects aging, lifestyle factors. CNN.
4. Global Prostate Cancer Market to Reach $50.3 Billion in 2017. Bcc Research.$50.3-billion-2017
5. Molecular Imaging Lights the Way for the Future of Medicine. NuView Life Sciences.
6. Recent Controversies in Mammography Screening for Breast Cancer. Medscape.


Media Inquiries:
Karla Jo Helms
Phone: 888-202-4614 ext. 802

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related medicine news :

1. Diet Doc’s Prescription Hormone Diets & Weight Loss Plans Announces New Clean Eating Diet Plans to Slim the Waistline While Reducing the Risk for Colorectal Cancer
2. Water Select® Raises Funds for Teen with Deadly Brain Cancer Known as Glioblastoma
3. Tree nut consumption associated with reduced risk of pancreatic cancer in women
4. Robots from space lead to 1-stop breast cancer diagnosis treatment
5. Online course improves physicians skill level for detecting skin cancer
6. AACR to host Annual Conference on Science of Cancer Health Disparities
7. Scientists at Cancer Prevention Institute of California Find That a Diet High in Fruits and Vegetables May Significantly Reduce Risk of Breast Cancer
8. Potential for added medical benefits uncovered for widely used breast cancer drug
9. UT Southwestern researchers discover a new driver of breast cancer
10. Hope builds for a drug that might shut down a variety of cancers
11. Mayo Clinic: Less-invasive option as effective as esophagus removal in early esophageal cancer
Post Your Comments:
(Date:6/13/2019)... ... June 13, 2019 , ... ... SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving ... being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose ...
(Date:6/12/2019)... ROCHELLE, Va. (PRWEB) , ... June 12, 2019 ... ... that Andrea Miller, a quality assurance expert with more than 25 years of ... and MDD Compliance for all classes of medical devices, has joined NDA Partners ...
(Date:6/12/2019)... ... June 12, 2019 , ... Ovation Travel Group, ... today announced that its Chairman and CEO Paul Metselaar has received the Children’s ... last Wednesday evening at New York City’s Capitale as part of the Children’s ...
(Date:6/12/2019)... ... June 12, 2019 , ... Millions of people across ... from participating in education or the workforce, and even from accessing health care. ... as a human right and address communication disability in ways that foster inclusion ...
(Date:6/11/2019)... ... 11, 2019 , ... The FSH Society today announced that ... regulators, biopharma companies, and academic thought leaders to discuss the current state of ... the world’s largest research-focused patient advocacy organization for FSHD, a hereditary muscle-damaging condition ...
Breaking Medicine News(10 mins):
(Date:6/11/2019)... , ... June 11, 2019 , ... ... Center and Grayken Center for Addiction will help combat the opioid epidemic by ... combines two pharmacy-specific educational interventions that have shown promise in reducing opioid-related harms, ...
(Date:6/11/2019)... ... June 11, 2019 , ... Intalere, ... today announced the latest enhanced release of OptiAnalytics Navigate. This best-in-class strategic ... customers. , “We are thrilled to offer these customer-focused new features ...
(Date:6/11/2019)... ... June 11, 2019 , ... MabPlex ... Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with sites in China ... the company's new Chief Executive Officer (CEO). Dr Chen will be responsible for ...
Breaking Medicine Technology: